Evidence map›Paper›PMID 33889280›Full record

ArticleWorld journal of gastrointestinal oncology2021

Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture.

Taichi Yoshida, Kentaro Takahashi, Kengo Shibuya, Osamu Muto, Yuko Yoshida, Daiki Taguchi, Kazuhiro Shimazu, Koji Fukuda, Fuminori Ono, Kyoko Nomura and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Taichi YoshidaDepartment ofClinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Kentaro TakahashiDepartment ofGastroenterological Surgery, Nakadori General Hospital, Akita 010-8577, Japan.
Kengo ShibuyaDepartment ofGastroenterology, Akita Kousei Medical, Akita 010-0948, Japan.
Osamu MutoDepartment ofMedical Oncology, Akita Red Cross Hospital, Akita 010-1495, Japan.
Yuko YoshidaDepartment ofMedical Oncology, Akita Red Cross Hospital, Akita 010-1495, Japan.
Daiki TaguchiDepartment ofClinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Kazuhiro ShimazuDepartment ofClinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Koji FukudaDepartment ofClinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Fuminori OnoDepartment ofSurgery, Omagari Kousei Medical Center, Akita 014-0027, Japan.
Kyoko NomuraDepartment ofEnvironmental Health Science and Public Health, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Hiroyuki ShibataDepartment ofClinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan. hiroyuki@med.akita-u.ac.jp.
Akita University · JPAkita Red Cross Hospital · JPNakadōri General Hospital · JPSendai Kousei Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAngiogenesis inhibitors (AIs) combination with cytotoxic chemotherapy is a promising treatment for patients with colorectal cancer (CRC). Aflibercept (AFL) is an option for second-line treatment of CRC, according to the 'VELOUR' trial. Currently, we can choose from three AIs, including bevacizumab, ramucirumab, and AFL. Different AIs can be used in subsequent treatment because of their distinctive mechanisms of action. We addressed the uncertainty regarding AFL efficacy and safety in heavily-treated patients by comparing outcomes of survival treatment with second-line treatment.

aimTo determine and compare the efficacy and safety profiles of AFL in the second-line and salvage therapy settings.

methodsClinical data of 41 patients with advanced CRC who received intravenous AFL combined with the folinic acid-fluorouracil-irinotecan (FOLFIRI) regimen were collected retrospectively from six institutions in Japan, for the period from May 2017 to March 2019. Patient characteristics collected included age, sex, tumor location,

resultsAll 41 patients who received AFL + FOLFIRI for advanced CRC had metastatic or unresectable cancer. Twenty-two patients received AFL in the second-line setting and nineteen in the salvage therapy setting. The patient characteristics were similar in the two groups, except for two factors. The median duration of the previous AI administration was shorter in the second-line patients compared with that in the salvage therapy patients (144 d

conclusionAFL can be used to treat advanced CRC patients, with a similar safety and efficacy in the salvage therapy setting as in the second-line setting.

Indexed as

AfliberceptColorectal cancerFolinic acid-fluorouracil-irinotecanObservational cohort studyPalliative chemotherapySecond-line chemotherapy

Identifiers

PMID33889280
PMCPMC8040061
OpenAlexW3153318101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.